Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. This dissertation investigates three interconnected aspects of PDAC biology and therapeutic targeting in the context of oncogenic KRAS. First, the thesis demonstrates that stromal-derived Neuregulin 1 (NRG1) activates upregulated ERBB2/3 receptors on cancer cells following KRAS inhibition, establishing a critical resistance pathway. Second, optimize tissue dissociation methodology was proposed for PDAC specimens, overcoming barriers created by the dense desmoplastic stroma to enable more effective isolation and characterization of tumor and stromal components. Last, the therapeutic potential of targeting the Hedgehog pathway in KRAS-mutant PDAC was investigated. Collectively, these findings advance understanding of tumor-microenvironment interactions in PDAC and provide a framework for novel combination therapeutic strategies targeting both oncogenic drivers and stromal resistance mechanisms.
","abstract_html":"<p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. This dissertation investigates three interconnected aspects of PDAC biology and therapeutic targeting in the context of oncogenic KRAS. First, the thesis demonstrates that stromal-derived Neuregulin 1 (NRG1) activates upregulated ERBB2/3 receptors on cancer cells following KRAS inhibition, establishing a critical resistance pathway. Second, optimize tissue dissociation methodology was proposed for PDAC specimens, overcoming barriers created by the dense desmoplastic stroma to enable more effective isolation and characterization of tumor and stromal components. Last, the therapeutic potential of targeting the Hedgehog pathway in KRAS-mutant PDAC was investigated. Collectively, these findings advance understanding of tumor-microenvironment interactions in PDAC and provide a framework for novel combination therapeutic strategies targeting both oncogenic drivers and stromal resistance mechanisms.</p>","abstract_has_math":false,"creators":["Han, Jincheng","0000-0002-7751-6158
"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation (PhD)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Ronald DePinho, M.D.","Jian Hu, Ph.D.","Haoqiang Ying, M.D., Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-08-01T07:00:00Z","date_published":"2025-08-01T07:00:00Z","updated_at":"2026-07-24T05:50:47Z","subjects":["Pancreatic cancer","Oncogenic KRAS","Resistance","Fibroblast","ERBB","Hedgehog signaling","Cancer Biology","Oncology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1473","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Ronald DePinho, M.D.","Jian Hu, Ph.D.","Haoqiang Ying, M.D., Ph.D."]},{"key":"dc:creator","label":"Author","values":["Han, Jincheng","0000-0002-7751-6158
"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2027-08-04T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation (PhD)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pancreatic cancer","Oncogenic KRAS","Resistance","Fibroblast","ERBB","Hedgehog signaling","Cancer Biology","Oncology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1473"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. This dissertation investigates three interconnected aspects of PDAC biology and therapeutic targeting in the context of oncogenic KRAS. First, the thesis demonstrates that stromal-derived Neuregulin 1 (NRG1) activates upregulated ERBB2/3 receptors on cancer cells following KRAS inhibition, establishing a critical resistance pathway. Second, optimize tissue dissociation methodology was proposed for PDAC specimens, overcoming barriers created by the dense desmoplastic stroma to enable more effective isolation and characterization of tumor and stromal components. Last, the therapeutic potential of targeting the Hedgehog pathway in KRAS-mutant PDAC was investigated. Collectively, these findings advance understanding of tumor-microenvironment interactions in PDAC and provide a framework for novel combination therapeutic strategies targeting both oncogenic drivers and stromal resistance mechanisms.
"]},{"key":"dc:title","label":"Title","values":["Targeting Stromal-Mediated Resistance Mechanisms in Oncogenic KRAS-Driven Pancreatic Ductal Adenocarcinoma"]}]}],"canonical_facts":{"dc:contributor":["Ronald DePinho, M.D.","Jian Hu, Ph.D.","Haoqiang Ying, M.D., Ph.D."],"dc:creator":["Han, Jincheng","0000-0002-7751-6158
"],"dc:date.available":["2027-08-04T07:00:00Z"],"dc:description.abstract":["Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. This dissertation investigates three interconnected aspects of PDAC biology and therapeutic targeting in the context of oncogenic KRAS. First, the thesis demonstrates that stromal-derived Neuregulin 1 (NRG1) activates upregulated ERBB2/3 receptors on cancer cells following KRAS inhibition, establishing a critical resistance pathway. Second, optimize tissue dissociation methodology was proposed for PDAC specimens, overcoming barriers created by the dense desmoplastic stroma to enable more effective isolation and characterization of tumor and stromal components. Last, the therapeutic potential of targeting the Hedgehog pathway in KRAS-mutant PDAC was investigated. Collectively, these findings advance understanding of tumor-microenvironment interactions in PDAC and provide a framework for novel combination therapeutic strategies targeting both oncogenic drivers and stromal resistance mechanisms.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1473"],"dc:subject":["Pancreatic cancer","Oncogenic KRAS","Resistance","Fibroblast","ERBB","Hedgehog signaling","Cancer Biology","Oncology"],"dc:title":["Targeting Stromal-Mediated Resistance Mechanisms in Oncogenic KRAS-Driven Pancreatic Ductal Adenocarcinoma"],"thesis:degree_level":["Dissertation (PhD)"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:50:47Z"}